The following table provides a brief history of GLP-1 therapies that have received FDA regulatory approval. In addition to identifying brand name, manufacturer and launch date, the chart shows whether the product received regulatory approval for weight loss or diabetes indications.
| Brand Name | Generic Name | Sponsor / Manufacturer | Indication | Launch Date |
|---|---|---|---|---|
|
Byetta |
exenatide |
AstraZeneca |
Diabetes |
4/28/05 |
|
Victoza |
liraglutide |
Novo Nordisk |
Diabetes |
1/25/10 |
|
Bydureon |
exenatide |
AstraZeneca |
Diabetes |
1/27/12 |
|
Tanzeum |
albiglutide |
GSK |
Diabetes |
4/15/16 |
|
Trulicity |
dulaglutide |
Eli Lilly |
Diabetes |
9/18/24 |
|
Saxenda |
liraglutide |
Novo Nordisk |
Weight Loss |
12/23/14 |
|
Adlyxin |
lixisenatide |
Sanofi |
Diabetes |
7/27/20 |
|
Bydureon Bcise |
exenatide |
AstraZeneca |
Diabetes |
10/20/17 |
|
Ozempic |
semaglutide |
Novo Nordisk |
Diabetes |
12/15/17 |
|
Rybelsus |
semaglutide |
Novo Nordisk |
Diabetes (oral formulation) |
1/16/20 |
|
Wegovy |
semaglutide |
Novo Nordisk |
Weight Loss |
6/4/21 |
|
Mounjaro |
tirzepatide |
Eli Lilly |
Diabetes |
5/13/22 |
|
Zepbound |
tirzepatide |
Eli Lilly |
Weight Loss |
11/8/23 |
*Products shaded in grey are no longer on the market.